One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Centessa Pharma ADR now clears that threshold, with a jump from 70 to 84 Thursday.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matches up against other publicly traded companies.
Decades of market research shows that the top-performing stocks often have an 80 or higher RS Rating in the early stages of their moves.
Centessa Pharma ADR is building a cup without handle with a 19.09 entry. See if it can break out in heavy trading.
The company showed 0% EPS growth in its most recent report. Revenue increased -100%. The next quarterly results are expected on or around Aug. 18.
Centessa Pharma ADR holds the No. 10 rank among its peers in the Medical-Research Equipment/Services industry group. Medpace Holdings, IQVIA Holdings and Charles River Labs Intl are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
